{Reference Type}: Journal Article
{Title}: Nebivolol/valsartan combination for the treatment of hypertension: a review.
{Author}: Wang SJ;Sander GE;
{Journal}: Future Cardiol
{Volume}: 17
{Issue}: 4
{Year}: 07 2021
暂无{DOI}: 10.2217/fca-2020-0079
{Abstract}: Nebivolol (N) is a β1-adrenoreceptor antagonist that is approved for treatment of hypertension in the USA. Effective treatment of hypertension is becoming an increasingly difficult process that often requires multiple drug combinations to meet target guidelines. This has resulted in the increasing introduction of multidrug single-pill combinations (SPCs) to facilitate cost and compliance issues. Some of the SPCs have added valsartan (V), an angiotensin receptor blocker, which is an increasingly advocated antihypertensive class. Pharmacological profiles of N and V, alone and combined, are well characterized. In 2007, the SPC of N and V, 5 and 80 mg, respectively, was approved by the US FDA for treatment of hypertension. This paper will summarize and update key issues in pharmacology, clinical use and benefit.